Respiratory motion management for radiotherapy of pancreatic cancer patients
Lens, E.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Chapter 4

Probabilistic treatment planning for pancreatic cancer treatment: prospective incorporation of respiratory motion shows only limited dosimetric benefit

Eelco Lens¹, Alexis NTJ Kotte², Ajay Patel², Hanne D Heerkens², Matthieu Bal³, Geertjan van Tienhoven¹, Arjan Bel¹, Astrid van der Horst¹, Gert J Meijer²

¹Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
²Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands
³Philips Healthcare, Eindhoven, the Netherlands

Adapted from: Acta Oncologica 2017;56:398–404
Abstract

Background
We introduced a probabilistic treatment planning approach that prospectively incorporates respiratory-induced motion in the treatment plan optimization. The aim of this study was to determine the potential dosimetric benefit by comparing this approach to the use of an internal target volume (ITV).

Material and Method
We retrospectively compared the probabilistic respiratory motion-incorporated (RMI) approach to the ITV approach for 18 pancreatic cancer patients, for seven simulated respiratory amplitudes from 5 to 50 mm in the superior-inferior (SI) direction. For each plan, we assessed the target coverage (required: D$_{98\%}$ ≥ 95% of 50 Gy prescribed dose). For the RMI plans, we investigated whether target coverage was robust against daily variations in respiratory amplitude. We determined the distance between the clinical target volume and the 30 Gy isodose line (i.e. dose gradient steepness) in the SI direction.

To investigate the clinical benefit of the RMI approach, we created for each patient an ITV and RMI treatment plan for the 3-dimensional respiratory amplitudes observed on their pre-treatment 4DCT. We determined D$_{mean}$, V$_{30Gy}$, V$_{40Gy}$ and V$_{50Gy}$ for the duodenum.

Results
All treatment plans yielded good target coverage. The RMI plans were robust against respiratory amplitude variations up to 10 mm, as D$_{98\%}$ remained ≥ 95%. We observed steeper dose gradients compared to the ITV approach, with a mean decrease from 25.9 to 19.2 mm for a motion amplitude of 50 mm. For the 4DCT motion amplitudes, the RMI approach resulted in a mean decrease of 0.43 Gy, 1.1 cm$^3$, 1.4 cm$^3$ and 0.9 cm$^3$ for the D$_{mean}$, V$_{30Gy}$, V$_{40Gy}$ and V$_{50Gy}$ of the duodenum, respectively.

Conclusion
The probabilistic treatment planning approach yielded significantly steeper dose gradients and therefore significantly lower dose to surrounding healthy tissues than the ITV approach. However, the observed dosimetric gain for clinically observed respiratory motion amplitudes for this patient group was limited.
Introduction

In pancreatic cancer treatment, pretreatment multi-modality imaging enables for precise target
definition and image-guided radiation therapy allows for accurate positioning of the patient. For
example, by using daily cone beam computed tomography (CBCT) scans together with intratumoral
fiducials, the uncertainties due to interfractional position variations of the tumor can be reduced
substantially [1,2]. An important remaining uncertainty is the respiratory-induced tumor motion [3].

Using an internal target volume (ITV) based on a single 4-dimensional (4D)CT measurement
to account for the respiratory motion is highly conservative and could lead to unnecessary high doses
to surrounding organs at risk (OARs) [4]. Alternatively, gating or real-time tracking of the tumor
could be used. These procedures can yield good results, but are also technically challenging and not
possible on all treatment machines [5,6].

Another approach would be to prospectively incorporate the respiratory-induced tumor motion
directly into the treatment plan optimization process to achieve an optimal, patient specific, solution
given the respiratory motion. This way the margins related to respiratory motion could be omitted.
To apply this method, an adaptation of the treatment planning system as well as information about
the expected tumor motion is needed. Several groups have proposed such adaptations to account
for geometric uncertainties [7–13]. These methods mainly focused on systematic and interfractional
uncertainties. In addition, all clinical data used to evaluate the methods were for prostate cancer
patients and none showed the practicability for respiratory motion of abdominal tumors. Jin et al.
showed that delivering an inhomogeneous dose distribution to lung tumors can result in a steeper
dose gradient around the target volume in the presence of respiratory motion [14]. Inverse treatment
planning while prospectively incorporating the respiratory motion has been shown to be beneficial,
but this has only been demonstrated in a limited number of lung cancer patients and only in a single
liver cancer patient [15–17]. Therefore, clear evidence of the dosimetric benefit of using probabilistic
planning for gastrointestinal tumors is still lacking. To determine the potential dosimetric benefit,
probabilistic planning should be systematically compared to a margin based approach for a larger
patient cohort and a large range of respiratory motion amplitudes. Also, before probabilistic
planning can be used in the clinic, its robustness against variations in the respiratory motion must be
investigated.

We developed a probabilistic treatment planning approach that prospectively accounts for the
respiratory-induced motion of upper-abdominal tumors in the optimization process. This respiratory
motion incorporated (RMI) approach was tested and compared to the ITV approach in a group of
pancreatic cancer patients using a wide range of simulated and clinically observed motion amplitudes.
The goal of this study was to investigate whether the RMI approach yielded clinically acceptable plans
that were robust against changes in respiratory motion amplitude. In addition, we investigated the
potential dosimetric benefit of the RMI approach compared to the ITV approach.
Chapter 4

Materials and Methods

Treatment plan optimization incorporating target motion
A plugin was developed for the Pinnacle (version 9.710) treatment planning software that incorporates respiratory-induced tumor motion directly into the optimization process of the inversely-optimized treatment planning. The blurring of the dose distribution with respect to the target volume as a result of the respiratory-induced motion is taken into account when determining the optimal dose distribution. This way, a static dose distribution is calculated that when delivered to the moving target, and thus convoluted with the respiratory motion kernel, will result in that optimal dose distribution. The used technique was similar to that described in previous studies [7–13]. A detailed description of the implemented algorithm is given in Appendix A.

Patient cohort and treatment planning
To evaluate the developed RMI approach and compare it to the ITV approach, we retrospectively studied a cohort of 18 patients who were diagnosed with resectable or borderline resectable pancreatic cancer. All patients had 2–4 intratumoral gold fiducial markers, had received a pre-treatment 4DCT scan and had tumor volumes ranging from 20 to 102 cm³ (mean: 53 cm³). The tumor of patient 5, 11 and 18 was located in the pancreatic body, body/tail and tail, respectively, all other tumors were located in the pancreatic head.

All created treatment plans were inversely optimized intensity modulated radiotherapy (IMRT) plans using 10 MV photons with beams from seven gantry angles divided evenly over a full 360° arc. For all plans, the prescription dose to the planning target volume (PTV) was set to 50 Gy. For the RMI plans this PTV was the clinical target volume (CTV), whereby the CTV comprised the gross tumor volume plus a 5 mm margin for microscopic spread. The ITV was created by expanding the CTV anisotropically using the corresponding respiratory-induced motion amplitude [18]. In this study, both the CTV-to-PTV and the ITV-to-PTV margin were set to 0 mm because we only considered the uncertainties due to respiratory motion. As a result, we directly used the ITV and the CTV as the PTV for the ITV and RMI approach, respectively.

The following objectives were used for optimization: a D_max of 51 Gy to the PTV (weight (w)=10), D_min of 50 Gy to the CTV (w=10), and D_max of 35 Gy to a 15 mm thick shell that was created at an isotropic distance of 6 mm around the PTV (w=1).

Simulated motion amplitudes
First, we investigated the robustness of the RMI approach against daily variations in tumor motion. Second, we systematically determined the potential dosimetric benefit of the RMI approach compared to the ITV approach. Both the robustness and dosimetric benefit were investigated using treatment plans based on seven simulated respiratory motion amplitudes up to 50 mm. The seven respiratory motion amplitudes (A=5, 10, 15, 20, 30, 40 and 50 mm) were used to create both ITV and RMI plans for each patient; this resulted in 14 treatment plans per patient, 252 plans in total. We only included
the respiratory motion in the superior-inferior (SI) direction and the PDFs describing the different motion amplitudes were based on a single motion trace (Fig. 4.1). This way, the comparison between the ITV and RMI approach could be made solely as a function of the respiratory motion amplitude. Also, we expected the greatest effect to be in the SI direction because here the dose gradient was steepest due to the planar irradiation technique that was used. We used the motion trace that described the respiratory-induced tumor motion in the SI direction of patient 10. This motion trace described the tumor motion as typically observed in the clinic on the 10 phase scans of a 4DCT (i.e. a smooth continuous curve with the average tumor position in phase 2 and the exhale position in phase 6). The PDFs describing the different motion amplitudes were obtained by scaling the motion trace to simulate different peak-to-peak amplitudes. The probability of each tumor position was 0.1 and the tumor position in the respiratory phase that contains the tumor in its position closest to the mean position (i.e. tumor position in phase 2) was set to zero. To simulate the delivery of the treatment plan to a moving target (e.g. pancreatic tumor during free breathing) all dose distributions were convolved with the PDF that was also used for the treatment plan optimization, in order to obtain the final dose distributions [19].

![Fig. 4.1: The motion trace describing the respiratory-induced tumor motion in inferior-superior direction for the 10 respiratory phases, as used for the simulated amplitudes. The motion trace is normalized to yield a peak-to-peak amplitude of 1; phase 1: end-inhale, phase 6: end-exhale.](image-url)
To determine whether the RMI approach yielded clinically acceptable plans, we determined for each plan whether target coverage was obtained, with target coverage defined as \(D_{98\%} \geq 95\%\) (i.e. the dose to 98% of the CTV should be at least 47.5 Gy).

The observed respiratory motion amplitude can vary substantially between what was observed at treatment planning and what was observed during daily treatment [3]. In an earlier study we observed that during 17% out of a total of 401 treatment fractions the motion amplitude differed \(\geq 5\) mm compared to what was observed during treatment planning [3]. We investigated the extent to which the RMI plans were robust in terms of target coverage against the daily variations in tumor motion. We analyzed the effect on the target coverage of applying a different respiratory motion amplitude for the convolution of the optimized dose distribution (i.e. treatment delivery simulation) than was used for treatment plan optimization. Since we used a single motion trace to describe tumor motion, and the main difference between patients was the tumor size, we demonstrated the robustness for the smallest (patients 12) and largest tumor (patient 17), only. For both patients, each of the seven dose distributions, optimized for a specific respiratory motion amplitude ranging from 5–50 mm, was convolved with eight PDFs (corresponding to amplitudes ranging from 0–50 mm), resulting in 56 different combinations per patient. For each combination, \(D_{98\%}\) of the CTV was determined. We did not investigate the robustness against variations in the motion amplitude in all three directions since we expected the largest variations in the SI direction [3]. Also, because the dose gradient was steepest in the SI direction, variations in respiratory amplitudes in that direction will have the greatest effect on target coverage.

We systematically determined the difference in dose gradient steepness in the SI direction of the RMI approach compared to the ITV approach for respiratory motion amplitudes of up to 50 mm. We obtained the maximum distance in the inferior direction between the CTV and the 30 Gy isodose line was determined in the coronal CT slice that contained the isocenter of the treatment plan and used as a measure for dose gradient steepness. This distance was chosen as a measure for gradient steepness because it also gave information on whether the high dose volumes were conform to the CTV, whereas the distance between two isodose lines, which is often used to describe the dose gradient, does not. For each analyzed respiratory motion amplitude, the average and standard deviation of the steepness over all patients were determined and plotted, for ITV and RMI separately. For each motion amplitude, the statistical significance of the difference of the dose gradient steepness between the RMI and the ITV approach was tested using the Wilcoxon signed-rank test.

To illustrate the potential dosimetric benefit of using the RMI approach for the surrounding OARs, we analyzed the \(D_{\text{mean}}\), \(V_{30\text{Gy}}\), \(V_{40\text{Gy}}\), and \(V_{50\text{Gy}}\) of the duodenum for all ITV and RMI plans for patient 12 and 17 (i.e. smallest and largest tumor, respectively). We determined the differences in the four dosimetric parameters of the duodenum between the RMI and ITV approach for all simulated respiratory-induced motion amplitudes. The Wilcoxon signed-rank test was used to test whether these differences were statistically significant.
Clinically observed 3-dimensional motion amplitudes

To determine the benefit of the RMI approach compared to the ITV approach in a more clinical setting, we also created treatment plans using clinically observed respiratory motion amplitudes. Two treatment plans were made for each patient that were based on the 3-dimensional (i.e. SI, anterior-posterior (AP) and left-right (LR)) respiratory-induced motion as was observed on the clinically used pre-treatment 4DCT scan; one using the ITV approach and one using the RMI approach. Again, all dose distributions were convolved with the PDF that was also used for the treatment plan optimization, to simulate the respiratory motion during treatment delivery [19].

To investigate the dosimetric benefit of the RMI approach for clinically observed respiratory motion amplitudes compared to the ITV approach, we determined the difference in dose to the duodenum. The duodenum was the OAR that was positioned closest to the PTV and for which the dose was expected to be influenced the most by a difference in dose gradient around the PTV. The $D_{\text{mean}}$, $V_{30\text{Gy}}$, $V_{40\text{Gy}}$ and $V_{50\text{Gy}}$ of the duodenum were analyzed for all ITV and RMI plans. The Wilcoxon signed-rank test was used to test whether these differences were statistically significant and Bland-Altman plots were created to visualize the differences.

Results

Simulated motion amplitudes

All RMI plans had good target coverage ($D_{\text{95\%}}>95\%$) when the dose distribution was convolved with the same PDF as was used for the optimization procedure. Figures B4.1a–f and B4.2a–f (Appendix B) show, for patient 12 and 17, three examples of RMI dose distributions, for respiratory motion amplitudes of 5, 20 and 50 mm in the SI direction. The static dose distributions (before convolution) can be highly inhomogeneous and the regions receiving high dose can extend to outside the target volume. After convolution, the distributions were homogeneous and conform to the CTV. For the ITV plans, the dose distributions were more conform to the CTV (Figs. B4.1g–l and B4.2g–l) after convolution.

The target coverage of the RMI plans was robust when the anticipated respiratory motion amplitude was ≤20 mm and the amplitude during treatment delivery was either ≤10 mm smaller or ≤5 mm larger (Fig. 4.2). This was within the range of clinically expected amplitude variations.

The use of the RMI approach resulted in significantly ($p \leq 0.0002$) steeper dose gradients for each simulated motion amplitude compared to the use of the ITV approach (Fig. 4.3). A difference in the dose gradient of 1.7 mm (respiratory motion amplitude of 5 mm) up to 6.7 mm (amplitude of 50 mm) was observed. Both approaches show a strong linear relationship ($r^2 \geq 0.995$) between the respiratory motion amplitude and the steepness of the dose gradient. The small standard deviations in the distance over all 18 patients (error bars, Fig. 4.3) indicate there is little effect of tumor volume on the steepness of the dose gradient around the CTV.

Table 4.1 shows the results for the evaluated dosimetric parameters of the duodenum for patient
Chapter 4

12 and patient 17, for both the ITV and the RMI approach when using the simulated respiratory amplitudes. All parameters decreased significantly \((p \leq 0.016)\), up to 51\% for the \(V_{50Gy}\) of patient 17 for a respiratory amplitude of 50 mm, when using the RMI instead of the ITV approach.

Clinically observed 3-dimensional motion amplitudes

The mean respiratory-induced motion amplitudes that were measured on the 4DCT and used to determine the clinical benefit were 2.4 (standard deviation: 1.1; range: 0.6–4.6) mm, 3.0 (1.0; 1.2–5.0) mm and 8.8 (3.3; 4.0–16.2) mm in LR, AP and SI, respectively. When applying these clinically observed respiratory motion amplitudes, the analyzed \(D_{98\%}\), \(V_{30Gy}\), \(V_{40Gy}\) and \(V_{50Gy}\) parameters for the duodenum decreased by 0.43 Gy, 1.1 cm\(^3\), 1.4 cm\(^3\) and 0.9 cm\(^3\), respectively (Fig. 4.4). All differences, although statistically significant \((p \leq 0.009)\), were small and therefore not expected to have a high clinical impact.
Fig. 4.3: Steepness of the dose gradient in the superior-inferior direction, i.e. distance from the CTV to the 30 Gy isodose line, for the ITV and the RMI approach for the seven simulated respiratory motion amplitudes. Lines are linear fits to the mean values of each approach; error bars indicate the standard deviations over all 18 patients.

Table 4.1: Dosimetric parameters for the duodenum for patients 12 and 17, for both the ITV and RMI approach (7 respiratory motion amplitudes each)

<table>
<thead>
<tr>
<th>A (mm)</th>
<th>ITV</th>
<th>RMI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D_{mean} (Gy)</td>
<td>V_{30Gy} (cm³)</td>
</tr>
<tr>
<td>Pat 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>34.1</td>
<td>55.5</td>
</tr>
<tr>
<td>10</td>
<td>35.6</td>
<td>58.7</td>
</tr>
<tr>
<td>15</td>
<td>36.9</td>
<td>61.7</td>
</tr>
<tr>
<td>20</td>
<td>38.0</td>
<td>64.3</td>
</tr>
<tr>
<td>30</td>
<td>39.6</td>
<td>68.4</td>
</tr>
<tr>
<td>40</td>
<td>40.7</td>
<td>72.5</td>
</tr>
<tr>
<td>50</td>
<td>41.2</td>
<td>74.5</td>
</tr>
<tr>
<td>Pat 17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>42.4</td>
<td>87.9</td>
</tr>
<tr>
<td>10</td>
<td>43.6</td>
<td>92.1</td>
</tr>
<tr>
<td>15</td>
<td>44.8</td>
<td>96.8</td>
</tr>
<tr>
<td>20</td>
<td>45.4</td>
<td>99.7</td>
</tr>
<tr>
<td>30</td>
<td>46.2</td>
<td>101.8</td>
</tr>
<tr>
<td>40</td>
<td>46.6</td>
<td>102.3</td>
</tr>
<tr>
<td>50</td>
<td>46.8</td>
<td>102.5</td>
</tr>
</tbody>
</table>

**Abbreviations:** ITV, internal target volume; RMI, respiratory motion incorporated; A, respiratory motion amplitude; Pat, patient.
Discussion

The developed treatment planning approach prospectively incorporated respiratory motion of pancreatic tumors in the optimization of the treatment planning process and generated treatment plans that were directly deliverable by a treatment machine. The created treatment plans resulted in inhomogeneous dose distributions when delivered to a static target. To simulate respiratory motion during treatment delivery, the dose distributions were convolved with the expected tumor motion. After convolution, these RMI plans yielded good target coverage, steeper dose gradients and therefore significantly lower dose to surrounding OARs when compared to the use of an ITV. This is in agreement with earlier results from the literature where the inferiority of the ITV was shown for a lung and a liver case [15]. However, for clinically observed respiratory-induced motion amplitudes, the differences in dose to the duodenum, which was in close proximity to the PTV and expected to be affected most by a change in the dose gradient, were small.

An earlier study showed that in clinical practice, 4DCT overestimates the respiratory-induced motion amplitude compared to the daily tumor motion for the majority of patients [3]. This
overestimate was typically in the range of 5–10 mm, with the amplitudes in the SI direction on 4DCT typically ≤20 mm. The current study shows that the RMI approach yielded clinically acceptable plans for moving targets that had a motion amplitude of up to 50 mm in the SI direction. In a clinical setting this approach would result in treatment plans that are robust in terms of target coverage against expected variations in respiratory amplitude, although the dose inhomogeneity might increase (Fig. 4.5). The ITV approach, inherently, will always yield sufficient target coverage and a homogeneous dose distribution when the motion amplitude during treatment is smaller than the amplitude used to create the ITV.

This study only considered rigid motion patterns, which limited the ability to accurately determine the benefit of using a probabilistic treatment planning approach for radiotherapy of pancreatic cancer. The developed approach can be extended to include anatomical deformations as well. However, the effects of deformations are expected to be minimal since it has been shown that the dosimetric differences, for both the target volume and healthy tissues, between using deformable image registration compared to rigid body translations are small in the upper-abdominal region [20]. The interplay effect between treatment delivery over time and tumor motion was neglected since this

![Fig. 4.5: For patients 12 (top) and 17 (bottom), dose distribution optimized for a simulated respiratory amplitude of 20 mm using the RMI approach (a and c) and the same distributions convolved with the PDF describing a simulated respiratory motion amplitude of 10 mm (b and d).](image)
does not affect the delivered dose [21].

The RMI approach resulted in a significant reduction of dose to the duodenum when compared to the ITV approach. High-dose volumes ($V_{50Gy}>1\,\text{cm}^3$ and $V_{50Gy}>16\,\text{cm}^3$) of the duodenum have been identified as strong predictors for toxicity [22,23]. The steeper dose gradient obtained by the RMI approach reduces these high-dose volumes, as was shown in this study. As the duodenum overlapped with the PTV for all patients, using the maximum dose as an evaluation parameter was not suitable to evaluate the difference between the ITV and RMI approach.

In an earlier study we showed that the use of a mid-ventilation approach for irradiation of pancreatic tumors can significantly reduce the dose to surrounding OARs while maintaining sufficient target coverage [18]. However, in the RMI approach the treatment planning system has the additional freedom to create initially inhomogeneous dose distributions, which can result in steep dose gradients in the final convolved dose distribution. The mid-ventilation approach merely applies smaller margins than the ITV approach and thus creates a homogeneous dose distribution. However, because in this study we compared the RMI approach to the ITV (a highly conservative technique) and we only observed minimal dosimetric gain, we expect the dosimetric difference between the mid-ventilation and RMI approach to be small. Further research is needed to determine which technique might be better in terms of robustness against variations in the respiratory amplitude and reducing the dose to OARs.

RMI planning and treatment requires accurate alignment of the mean tumor position during treatment with the expected mean tumor position from the planning CT scan. Because of the more conformal dose distributions compared to the use of an ITV, the dosimetric impact of a mismatch might be larger for the RMI approach. It is therefore recommended to daily position the patient by registration of the mean tumor position obtained from a daily 4D-CBCT with the mean tumor position during respiration obtained from a pre-treatment 4DCT combined with the use of intratumoral fiducials. For this daily position verification, small (i.e. $\varnothing = 0.28–0.35\,\text{mm}$) intratumoral fiducials that can be implanted during an endoscopic procedure can be used [1,2,24].

Our results show that our newly developed approach of prospectively incorporating respiratory-induced pancreatic tumor motion in the optimization process can yield more conformal dose distributions compared to the ITV approach. However, the dosimetric gain highly depends on the respiratory-induced motion amplitude; for the 18 patients for whom treatment plans were based on the clinical amplitudes, we observed only small differences in dose to the duodenum. When the respiratory motion amplitude becomes larger (i.e. $>15\,\text{mm}$) the dosimetric benefit becomes more substantial. In daily clinical practice, treatment planning combined with probabilistic optimization will likely result in only a minimal clinical gain and for each treatment site it should be determined what this gain on average would be. For pancreatic cancer patients, we recommend to use a probabilistic planning strategy only when the respiratory-induced motion amplitude is $>15\,\text{mm}$, which might occur in only a limited number of patients. For smaller amplitudes using a simple expansion of the target volume to account for the respiratory motion may be sufficient.
Conclusion

Prospective incorporation of respiratory-induced pancreatic tumor motion in the treatment plan optimization process resulted in treatment plans that had good target coverage and were robust against variations in the respiratory motion amplitude within a certain bandwidth. Probabilistic treatment plans had significantly steeper dose gradients and therefore yielded significantly lower dose to surrounding organs at risk compared to the use of an internal target volume. However, the potential clinical gain of this treatment planning technique for this patient group was limited.
Appendix A: Treatment plan optimization incorporating target motion

The optimization module in Pinnacle is based on a Quasi-Newton optimization approach. In short, the optimizer uses a cost function to calculate the total cost of a dose distribution based on predefined planning objectives. The gradient of this cost function is then calculated and the Hessian matrix is approximated using information from previous iterations to determine the search direction in the solution space towards a lower total cost.

Every predefined objective contributes to the cost function. If for example a region of interest (ROI) should receive at most/at least a certain dose level, this is expressed with the following quadratic objective function [25]:

\[ f(I) = w \sum_{i} u(d_i, d^p) \left( \frac{d_i - d^p}{d^p} \right)^2 v_i. \]  

(1)

With:

\[ \mu(d_i, d^p) = \begin{cases} H(d^p - d_i) & : \text{min dose function} \\ H(d_i - d^p) & : \text{max dose function} \end{cases}, \]

(2)

where \( w \) is the weight of the objective, \( H \) is the Heaviside function, \( d_i \) the dose at voxel \( i \), \( d^p \) the threshold dose and \( v_i \) the relative voxel volume where the index \( i \) runs over the voxels within \( V \), the volume to be evaluated. For regular maximum and minimum dose objectives, \( V \) is equal to the entire ROI in question; for DVH objectives, \( V \) only includes a fixed proportion of the high dose (or low dose) voxels, depending on a preset fractional threshold. The cost function is the sum of all objective functions for all ROIs of interest, with weights to assign the priority of each objective function. The gradient of the given objective function for one voxel is obtained by taking the derivative of this objective function with respect to the dose:

\[ \frac{\partial f(d)}{\partial d_i} = \mu(d_i, d^p) \frac{d_i - d^p}{(d^p)^2} \cdot 2v_i. \]

(3)

The gradient of the cost function is calculated and used to steer towards a new dose distribution that decreases the total cost [26]. The total cost converges to a minimum after multiple iterations. A change in dose is converted to a change in machine parameters by the optimizer, using pre-defined dose kernels. This way, the cost and its gradient are directly dependent on the machine parameters [26].

With respiratory motion present, the dose distribution with respect to the target volume will undergo blurring. This blurring of the dose is calculated by the optimizer by convoluting the dose with the probability density function (PDF) that describes the expected motion [19]. The blurred dose in a voxel \( i \) is the weighted sum of the dose of all voxels that contribute to voxel \( i \):
The dose to voxel $i$ in the blurred dose distribution is denoted by $\tilde{d}_i$. Voxel displacement is indicated by $j$ and $Z$ contains all translations $j$ of a voxel $i$ with a non-zero probability (i.e. the motion kernel). The probability of displacement $j$ is indicated by $p_j$, with $\sum_{j \in Z} p_j = 1$. Therefore, under moving conditions the objective function of equation (1) becomes:

$$f(\tilde{d}) = w \Sigma_{i \in V} \mu(d_i, d^p) \left(\frac{\tilde{d}_i - d^p_i}{d^p_i}\right)^2 v_i = w \Sigma_{i \in V} \mu(d_i, d^p) \left(\frac{\Sigma_{j \in Z} d_{i+j} p_j - d^p_i}{d^p_i}\right)^2 v_i. \quad \text{(5)}$$

The dose at each voxel is now evaluated for the blurred dose distribution. Due to motion, the dose that is deposited as a static distribution will be spread out amongst the voxels. The gradient of the objective function for one voxel is then expressed by the following equation:

$$\frac{\partial f(\tilde{d})}{\partial d_i} = \sum_{j \in Z} \mu(d_i, d^p) \left(\frac{d_i - d^p_{i+j}}{d^p_{i+j}}\right)^2 - 2v_{i-j} \cdot p_j. \quad \text{(6)}$$

A change in $d_i$ influences the dose in all voxels that after blurring have some contribution from voxel $i$. So, the gradient of the cost for the blurred dose is the weighted sum of the gradients of all voxels that are affected by a change in $d_i$. 
Appendix B: Supplementary figures

Fig. B4.1: Examples of the optimized dose distributions before and after convolution with the expected target motion for patient 12 (i.e. smallest tumor) for three simulated respiratory motion amplitudes (5, 20 and 50 mm in the superior-inferior direction), when using the respiratory motion incorporated (RMI) approach (a–f) or the internal target volume (ITV) approach (g–l). The CTV is indicated by the black contour.
Fig. B4.2: Examples of the optimized dose distributions before and after convolution with the expected target motion for patient 17 (i.e. largest tumor) for three simulated respiratory motion amplitudes (5, 20 and 50 mm in the superior-inferior direction), for both the respiratory motion incorporated (RMI) approach (a–f) and the internal target volume (ITV) approach (g–l). The black contour indicates the CTV.
References


